Clinical stage biotechnology company AnHeart Therapeutics has announced two new appointments.
The company, which develops novel precision oncology therapeutics, has appointed Heinrich Farin, M.D. as Senior Medical Director of Clinical Research and Michael J. Humphries, Ph.D., as VP and Head of US Medical Affairs.
Dr Farin has more than 20 years of experience in clinical development, directing complex global Phase I-IV clinical trials, including first-in-human through global studies, focusing on therapies in rare diseases.
Dr Humphries has experience in pre-and-post launch medical activities, strategic planning and execution, evidence generation, and drug discovery.
Junyuan (Jerry) Wang, Ph.D. CEO & Co-Founder, AnHeart Therapeutics, said:
“We’re delighted to welcome Drs. Farin and Humphries to AnHeart Therapeutics.
“Both Heinrich and Michael, seasoned leaders in drug development and with proven track records of success, will bring invaluable experience/expertise to our growing clinical development team.
“Both Heinrich and Michael previously worked with Dr. Li in the development of targeted therapy including mobocertinib, a first-in-class EGFR inhibitor that targeted EGFR exon 20 insertions and expanding the global development of ponatinib, a novel multi-tyrosine kinase inhibitor.”
Prior to joining AnHeart, Dr Farin led global development of anti-cancer therapies in solid tumours and leukaemia as Senior Medical Director at Mirati Therapeutics and Global Senior Medical Director, Clinical Research and Development at BeiGene.
Dr Humphries was most recently head of lung cancer, senior scientific director of global medical affairs at Takeda Oncology, where he led the lung cancer portfolio for brigatinib and mobocertinib.
Dr Farin said:
“I am excited to join AnHeart at this dynamic time.
“The company is developing multiple cancer therapies including its leading asset taletrectinib targeting ROS1-fusion and resistant mutations, and other gene mutations in other cancers.
“I look forward to contributing to AnHeart’s mission to improve the lives of cancer patients with breakthrough medicines and advancing global clinical programs.”
Dr Humphries said:
“It is great to work with both D. Li and Dr. Farin again, as we previously worked together while at Ariad Pharmaceuticals.
“Taletrectinib is a next-generation ROS-1 inhibitor that is a much-needed innovative therapy for patients with this subtype of non-small cell lung cancer.
“I look forward to working with the management and scientific teams to help bring this much needed therapy to cancer patients.”
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- Diagnostics4 weeks ago
3D model will advance understanding of spinal injury pathology
- Opinion1 week ago
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
- AI3 weeks ago
AI can help predict survival outcomes for cancer patients
- Research5 days ago
Tackling the diagnostic testing sustainability problem